Identifying effect modifiers of CAR-T cell therapeutic efficacy: a systematic review and individual patient data

Manoj M Lalu1,2, Natasha Kekre1,3, Joshua Montroy1

  • 1Centre for Practice-Changing Research, Office L1298a, Clinical Epidemiology Program, Ottawa Hospital Research Institute, 501 Smyth Road, Box 201B, Ottawa, Ontario, K1H 8L6, Canada.

Systematic Reviews
|January 18, 2023
PubMed
Abstract

Insights

This study systematically reviews chimeric antigen receptor T cell (CAR-T) therapy for blood cancers. It aims to identify patient and treatment factors influencing CAR-T efficacy and safety in relapsed/refractory patients.

Area of Science:

  • Hematologic Oncology
  • Immunotherapy
  • Clinical Trials

Background:

  • Chimeric antigen receptor T cell (CAR-T) therapy shows promise for hematologic malignancies but faces challenges with treatment response heterogeneity and safety concerns like cytokine release syndrome.
  • Identifying factors influencing CAR-T efficacy is crucial for the long-term sustainability of this complex therapy.
  • Individual patient data meta-analysis (IPDMA) can help explain response variability.

Purpose of the Study:

  • To conduct a systematic review and IPDMA of CAR-T cell therapy in patients with hematologic malignancies.
  • To explore potential patient- or treatment-specific factors that modify CAR-T cell therapy efficacy and safety.

Main Methods:

  • Systematic literature search of MEDLINE, Embase, and Cochrane Central Register of Controlled Clinical Trials.
  • Inclusion of prospective clinical trials of CAR-T therapy in hematologic malignancies, with duplicate screening and data extraction.
  • Primary outcome: complete response. Secondary outcomes: overall response, progression-free survival, overall survival, and safety. IPD meta-analysis using a one-stage approach.

Main Results:

  • This section is to be filled after the study is conducted.

Conclusions:

  • Identifying modifiers of CAR-T cell efficacy is paramount for optimizing future clinical trials.
  • Results will inform the development of more personalized and effective CAR-T treatment strategies.
  • Findings will be disseminated through peer-reviewed publications, conferences, and stakeholder engagement.

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
619
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.2K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
2.5K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.1K